We demonstrated that, besides decimating CML cells, imatinib also upregulates CXCR4 in CML cells, helping them to migrate to shelter sites in bone marrow stroma, where they revert to a G0-G1 cell cycle state and survive therapy [77]. This evidence concerns the gene CXCR4 and chronic myelogenous leukemia, BCR-ABL1 positive.